Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

Abstract

Breast cancer is a multifactor, multistage, and heterogeneous disease. Systemic treatment of breast cancer has changed significantly over the last decade. With a better knowledge of the pathogenesis, researchers and scientists have discovered numerous signaling pathways and synonymous therapeutic targets in breast cancer. Because of the molecular nature of breast cancer, which makes it difficult to understand, previous attempts to treat or prevent it have failed. However, recent decades have provided effective therapeutic targets for treatment. In this review, literature or information on various targeted therapy for breast cancer is discussed. English language articles were explored in numerous directory or databases like PubMed, Web of Sciences, Google Scholar, ScienceDirect, and Scopus. The important keywords used for searching databases are “Breast cancer,” “Targeted therapy in breast cancer,” “Therapeutic drugs in breast cancer,” and “Molecular targets in breast cancer.”

Keywords

breast cancer / targeted therapy in breast cance / therapeutic drugs in breast cancer / molecular targets in breast cancer / precision medicine in breast cancer

References

[1] Sledge Jr GW, Miller KD.Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003; 39(12) 1668-1675

[2] Ingvarsson S.Genetics of breast cancer. Drugs Today (Barc) 2004; 40(12) 991-1002

[3] Kenemans P, Verstraeten RA, Verheijen RHM.Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas 2004; 49(01) 34-43

[4] Eniu A.Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. J BUON 2007; 12(Suppl. 01) S119-S126

[5] Modi S, D'Andrea G, Norton L. et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7(03) 270-277

[6] Green MD, Francis PA, Gebski V.et al; Australian New Zealand Breast Cancer Trials Group. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol 2009; 20(11) 1813-1817

[7] Twelves C, Trigo JM, Jones R.et al.Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008; 44(03) 419-426

[8] van 't Veer LJ, Dai H, van de Vijver MJ.et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871): 530-536

[9] Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200(03) 290-297

[10] Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN.The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14(04) 320-368

[11] Untch M, Rezai M, Loibl S.et al.Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28(12) 2024-2031

[12] Ishida T, Kiba T, Takeda M.et al.Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 2009; 64(02) 361-369

[13] Michalaki V, Fotiou S, Gennatas S, Gennatas C.Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. Anticancer Res 2010; 30(07) 3051-3054

[14] Lee-Hoeflich ST, Crocker L, Yao E.et al.A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68(14) 5878-5887

[15] Blackwell KL, Burstein HJ, Storniolo AM.et al.Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28(07) 1124-1130

[16] Carey LA, Berry DA, Cirrincione CT.et al.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2016; 34(06) 542-549

[17] Scaltriti M, Chandarlapaty S, Prudkin L.et al.Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010; 16(09) 2688-2695

[18] Sutherland S, Ashley S, Miles D.et al.Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 2010; 102(06) 995-1002

[19] Batus M, Fidler MJ, Bonomi PD.Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther 2010; 10(10) 1589-1599

[20] Gianni L, Lladó A, Bianchi G.et al.Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28(07) 1131-1137

[21] Wong KK, Fracasso PM, Bukowski RM.et al.A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009; 15(07) 2552-2558

[22] 22 Smaill JB, Palmer BD, Rewcastle GW.et al. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999; 42(10) 1803-1815

[23] Schlam I, Swain SM.HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer 2021; 7(01) 56

[24] Ulrich L, Okines AFC.Treating advanced unresectable or metastatic HER2-positive breast cancer: a spotlight on tucatinib. Breast Cancer (Dove Med Press) 2021; 13: 361-381

[25] Lu H, Shu XO, Cui Y.et al.Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65(12) 5015-5019

[26] Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL.Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27(30) 4966-4972

[27] Miles DW, Chan A, Dirix LY.et al.Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28(20) 3239-3247

[28] Valero V, Forbes J, Pegram MD.et al.Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29(02) 149-156

[29] Burstein HJ, Elias AD, Rugo HS.et al.Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26(11) 1810-1816

[30] Slamon D, Gomez HL, Kabbinavar FF.et al.Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008; 26: 1016-1017

[31] Rugo H, Stopeck A, Joy A, Chan S.A randomized, double blind phase II study of the oral tyrosine kinase inhibitoraxitinib (AG013736) in combination with docetaxel compared to docetaxel plus placebo in metastatic breast cancer. J Clin Oncol 2007 2011; 29(18) 2459-2465

[32] Miller KD, Trigo JM, Wheeler C.et al.A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11(09) 3369-3376

[33] Johnston SR, Hickish T, Ellis P.et al.Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21(13) 2492-2499

[34] Moreno-Aspitia A, Morton RF, Hillman DW.et al.Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009; 27(01) 11-15

[35] Gong C, Zhao Y, Wang B.et al.Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. Oncotarget 2017; 8(35) 59810-59822

[36] Kwitkowski VE, Prowell TM, Ibrahim A.et al.FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15(04) 428-435

[37] Chan S, Scheulen ME, Johnston S.et al.Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23(23) 5314-5322

[38] Fleming GF, Ma CX, Huo D.et al.Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2012; 136(02) 355-363

[39] Di Leo A, Johnston S, Lee KS.et al.Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19(01) 87-100

[40] Baselga J, Im SA, Iwata H.et al.Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(07) 904-916

[41] Saura C, Roda D, Roselló S.et al.A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov 2017; 7(01) 102-113

[42] Zhang M, Jang H, Nussinov R.PI3K inhibitors: review and new strategies. Chem Sci (Camb) 2020; 11(23) 5855-5865

[43] Schöffski P, Cresta S, Mayer IA.et al.A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res 2018; 20(01) 109

[44] Chollet P, Abrial C, Tacca O.et al.Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006; 7(04) 336-338

[45] Brünner-Kubath C, Shabbir W, Saferding V.et al.The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011; 129(02) 387-400

[46] Fornier MN, Rathkopf D, Shah M.et al.Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13(19) 5841-5846

[47] Liang Y, Besch-Williford C, Hyder SM.PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009; 35(05) 1015-1023

[48] Erlichman C, Adjei AA, Alberts SR.et al.Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 2001; 12(03) 389-395

[49] Finn RS, Bengala C, Ibrahim N.et al.Phase II trial of dasatinib in triple-negative breastcancer: Results of study CA 180059. Cancer Res 2009; 69: 237s

[50] Chen Y, Alvarez EA, Azzam D.et al.Combined Src and ER blockade impairs humanbreast cancer proliferation in vitro and in vivo . Breast Cancer Res Treat 2010

[51] Modi S, Stopeck AT, Gordon MS.et al.Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25(34) 5410-5417

[52] Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL.IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13(18 Pt 2): 5549s-5555s

[53] Rowe DL, Ozbay T, Bender LM, Nahta R.Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther 2008; 7(07) 1900-1908

[54] Munster PN, Marchion D, Thomas S.et al.Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009; 101(07) 1044-1050

[55] Münster P, Marchion D, Bicaku E.et al.Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25(15) 1979-1985

[56] Goel S, DeCristo MJ, Watt AC. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 2017; 548(7668): 471-475

[57] Finn RS, Martin M, Rugo HS.et al.Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375(20) 1925-1936

[58] Dickler MN, Tolaney SM, Rugo HS.et al.MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 2017; 23(17) 5218-5224

RIGHTS & PERMISSIONS

2023 Global Medical Genetics